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Cordycepin interferes with 3' end formation in yeast
independently of its potential to terminate RNA chain elongation
Abstract
Cordycepin (3' deoxyadenosine) is a biologically active compound that, when incorporated during RNA
synthesis in vitro, provokes chain termination due to the absence of a 3' hydroxyl moiety. We were
interested in the effects mediated by this drug in vivo and analyzed its impact on RNA metabolism of
yeast. Our results support the view that cordycepin-triphosphate (CoTP) is the toxic component that is
limiting cell growth through inhibition of RNA synthesis. Unexpectedly, cordycepin treatment
modulated 3' end heterogeneity of ACT1 and ASC1 mRNAs and rapidly induced extended transcripts
derived from CYH2 and NEL025c loci. Moreover, cordycepin ameliorated the growth defects of
poly(A) polymerase mutants and the pap1-1 mutation neutralized the effects of the drug on gene
expression. Our observations are consistent with an epistatic relationship between poly(A) polymerase
function and cordycepin action and suggest that a major mode of cordycepin activity reduces 3' end
formation efficiency independently of its potential to terminate RNA chain elongation. Finally,
chemical-genetic profiling revealed genome-wide pathways linked to cordycepin activity and identified
novel genes involved in poly(A) homeostasis.
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Cordycepin interferes with 39 end formation in yeast
independently of its potential to terminate RNA chain
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ABSTRACT
Cordycepin (39 deoxyadenosine) is a biologically active compound that, when incorporated during RNA synthesis in vitro,
provokes chain termination due to the absence of a 39 hydroxyl moiety. We were interested in the effects mediated by this drug
in vivo and analyzed its impact on RNA metabolism of yeast. Our results support the view that cordycepin-triphosphate (CoTP)
is the toxic component that is limiting cell growth through inhibition of RNA synthesis. Unexpectedly, cordycepin treatment
modulated 39 end heterogeneity of ACT1 and ASC1 mRNAs and rapidly induced extended transcripts derived from CYH2 and
NEL025c loci. Moreover, cordycepin ameliorated the growth defects of poly(A) polymerase mutants and the pap1-1 mutation
neutralized the effects of the drug on gene expression. Our observations are consistent with an epistatic relationship between
poly(A) polymerase function and cordycepin action and suggest that a major mode of cordycepin activity reduces 39 end
formation efficiency independently of its potential to terminate RNA chain elongation. Finally, chemical-genetic profiling
revealed genome-wide pathways linked to cordycepin activity and identified novel genes involved in poly(A) homeostasis.
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INTRODUCTION
The adenosine analog cordycepin (39 deoxyadenosine) was
first isolated from the ascomycete fungus Cordyceps mili-
taris (Cunningham et al. 1950). Due to the absence of a
39-hydroxyl moiety, the incorporation of cordycepin dur-
ing RNA synthesis will result in termination of chain elon-
gation. This activity has been well described in vitro with
purified RNA polymerases and poly(A) polymerases from a
number of organisms including yeast (Horowitz et al.
1976) and mammals (Muller et al. 1977). Furthermore,
cordycepin exhibits well-established anti-bacterial, anti-
fungal, and anti-parasitic properties (Sugar and McCaffrey
1998; Ahn et al. 2000; Rottenberg et al. 2005). In humans,
anti-oxidant, anti-inflammatory, and anti-proliferative activ-
ities have been attributed to the drug (Zhu et al. 1998a,b).
Indeed, for centuries, the fungus Cordyceps sinensis has been
a widely administered traditional Chinese medicine, and
cordycepin is thought to be one of the bioactive components
mediating a host of beneficial effects (Paterson 2008). While
the therapeutic potential of cordycepin underscores its
unique properties, the effects of the drug on RNA metab-
olism are not completely understood. However, cordycepin
was previously used to screen for novel genes involved in
pre-mRNA polyadenylation (Bloch et al. 1978). This iden-
tified RNA14 and RNA15 genes, which encode core compo-
nents of the 39 end formation machinery in yeast (Minvielle-
Sebastia et al. 1994). Thus, cordycepin responsive growth
phenotypes may be useful indicators to detect deficiencies in
pre-mRNA processing.
In this work, we present the first comprehensive analysis
of the molecular effects of cordycepin in the budding yeast
Saccharomyces cerevisiae. We provide evidence that the drug
interfered with RNA synthesis and that this effect is
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mediated by CoTP, the toxic derivative of cordycepin.
Unexpectedly, we observed defects during 39 end formation
of transcripts that occurred independently of a possible role
of CoTP in terminating RNA chain elongation. Genome-
wide chemical genetic profiling identified mutations that
mediated cordycepin-responsive growth and linked novel
genes to poly(A) metabolism. Our results extend the un-
derstanding of the molecular effects of the drug and
establish cordycepin responsive growth as a functional test
for the characterization of unknown genes.
RESULTS
Cordycepin toxicity in yeast is due to the inhibition
of RNA synthesis
To analyze the molecular effects of cordycepin, we initially
testedmutants in RNA synthesis pathways for hypersensitive
growth in the presence of the drug (Fig. 1A). In these
experiments, we employed a concentration of 20 mg/mL
cordycepin, which only mildly affected growth of a wild-type
strain (10% increased doubling time in liquid culture) (data
not shown). We observed hypersensitive growth associated
with mutants in the largest subunit of RNAP II (rpb1-1),
kinases that phosphorylate the serine 5 (kin28-ts3) and serine
2 residues (Dctk1) of the RNAP II carboxy-terminal domain
(CTD), a serine 5 CTD phosphatase (ssu72-2), and the
nuclear 59–39 exonuclease Rat1 (rat1-1). Furthermore, mu-
tants in certain 39 end formation components responded
strongly to the drug. This included the rna14-1 and rna15-1
strains, which were initially identified based on cordycepin
sensitivity (Bloch et al. 1978), a mutation in the putative
39 end nuclease Ysh1/Brr5 (ysh1-3), and the 39 end factor
Ref2 (Dref2). In contrast, mutation of Yhh1/Cft1 (yhh1-3)
was without effect, and a mutant in poly(A) polymerase
(pap1-2) showed increased resistance to cordycepin. To cor-
roborate the latter observation, we tested additional mutant
alleles in poly(A) polymerase and found that the pap1-2 and
pap1-7 mutants reproducibly displayed a distinct growth
advantage at 33°Con cordycepinmedium (Fig. 1B).With the
exception of the paradoxical behavior of pap1 mutants,
cordycepin enhanced the growth defects of mutations in
transcription and pre-mRNA 39 end formation, consistent
with a negative impact on RNA synthesis.
While the enhancement of growth defects linked cordy-
cepin activity to RNA metabolism, it is less clear whether
inhibition of RNA synthesis is the reason for reduced cell
growth. To get a better understanding of cordycepin tox-
icity, we identified mutations that ameliorated the in-
hibitory effects of the drug (see below). Consistent with
previous results (Lecoq et al. 2001), we found that the
absence of the adenosine kinase Ado1 suppressed cordyce-
pin toxicity at high cordycepin concentrations that reduced
growth of a wild-type strain (Fig. 1C, 120 mg/mL). Ado1
converts cordycepin to cordycepin-monophosphate (CoMP),
which is transformed into cordycepin-triphosphate (CoTP)
by adenylate kinase Adk1 (Konrad 1988). Since Dadk1
cells were also resistant to cordycepin (see below), we
conclude that CoTP, rather than cordycepin, is the toxic
component. Strikingly, we found that the absence of
various components involved in cytoplasmic mRNA turn-
over also suppressed cordycepin toxicity. This included
the 59–39 exonuclease Xrn1 (Muhlrad et al. 1994), the
Pop2 deadenylase (Daugeron et al. 2001), and Ski2 and
Ski3/5 proteins that aid exosome mediated (39–59 directed)
RNA turn over (Brown et al. 2000). The observation that
RNA stabilization suppressed cordycepin toxicity is con-
sistent with the idea that RNA synthesis is limiting cell
growth in the presence of the drug.
Effects of cordycepin on mRNA synthesis
in wild-type strains
Next, we exposed wild-type strains to 20 mg/mL cordycepin
and performed RNA analyses. Cellular poly(A) content was
FIGURE 1. Cordycepin-responsive mutant yeast strains involved in
RNA synthesis and turn-over. (A–C) The indicated yeast strains were
grown overnight in synthetic complete (SD) medium at the appro-
priate temperature. Tenfold serial dilutions were produced and
spotted on media lacking or containing cordycepin and grown for
3–5 d. Unless indicated otherwise, the cordycepin concentration used
was 20 mg/mL.
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strongly reduced after 2 h, consistent with a strong in-
hibition of RNA synthesis (Fig. 2A). Probing of individual
housekeeping mRNAs by Northern blot revealed reduced
steady-state levels for CYH2, ASC1, and ADH1 and a less
severe effect on ACT1 and the stable PGK1 mRNA (Fig.
2B); levels of 18S rRNA, U3 snoRNA, and tRNA3
LEU
remained unchanged (Fig. 2B; data not shown). Most
interestingly, we observed additional, longer RNAs for
CYH2, which appeared as early as 15 min after cordycepin
addition. These RNAs extended more than 3 kb beyond the
normal 39 end of the mRNA. Furthermore, a probe directed
against the CYH2 intron readily detected the pre-mRNA and
extended transcripts (Fig. 2B).
Moreover, we observed a pattern of ACT1 mRNA in the
presence of cordycepin that was reminiscent of poly(A) site
selection defects previously associated with mutants in the
39 end formation machinery (Mandart and Parker 1995;
Dichtl et al. 2002b; Kyburz et al. 2003). To analyze the 39 ends
of ACT1 , we targeted the RNA with an oligonucleotide
directed against the open reading frame (ORF) and RNase H
(Fig. 2C). This resulted in 59 truncation of the mRNA and
allowed the size separation on high-resolution gels of tran-
scripts with at least five different 39 ends (Dichtl et al. 2002b).
In the absence of cordycepin site I was used predominately,
but addition of the drug triggered the disappearance of this
species and the accumulation of longer transcripts, which
mostly use site V. Notably, this effect was not observed with
Dado1 cells (data not shown), suggesting that CoTP may be
the active compound mediating this effect. Interestingly, a
similar phenotype was observed with ASC1 mRNA. This
transcript also displayed heterogeneous 39 ends in wild-type
strains, and we could resolve at least four different RNA
species following RNaseH treatment as described above (Fig.
2C). In the absence of cordycepin the different transcripts
were roughly equal in abundance, but addition of the drug
resulted in exclusive usage of the most distal 39 end after 2 h.
These results suggested that cordycepin reduced the effi-
ciency of 39 end formation at a step prior to poly(A) tail
synthesis by poly(A) polymerase.
The pap1-1 mutation neutralizes the effects
of cordycepin on gene expression
Our results indicated complex effects of cordycepin on
RNA metabolism of yeast, and we were intrigued by its
mitigating effects on growth of poly(A) polymerase mu-
tants. To extend our experiments, we determined by
microarray analyses changes in RNA levels that were induced
within 1 h by 20 mg/mL cordycepin in wild-type and pap1-1
strains. The obtained data, depicted as a heat map in Figure
3A and as a scatter plot in Figure 3B, revealed a high
correlation of signals obtained with the pap1-1 strain in the
absence or presence of the drug, respectively. This suggested
that the pap1-1 mutation largely neutralized the negative
effects of cordycepin on gene expression. In contrast, the
effects of cordycepin treatment of wild-type and the effects
of the pap1-1 mutation were not correlated (Fig. 3A,B),
suggesting that the two conditions had distinct effects on
RNA levels.
FIGURE 2. Molecular effects of cordycepin on RNA metabolism. (A)
Cellular poly(A) length distribution following cordycepin treatment.
Total RNA was extracted from wild-type strains following growth in
the presence of 20 mg/mL cordycepin for the indicated times. RNAs
were labeled with [a-32P]cordycepin and poly(A) polymerase, and
digested with RNases A and T1. RNase-resistant poly(A) tails were
resolved on denaturing 15% polyacrylamide/8.3 M urea gels and
visualized by PhosphorImaging (Fuji FLA7000). (B) Northern analysis
of RNA obtained from a wild-type strain treated with cordycepin as
described in A. RNAs were detected with random prime labeled
probes directed against the open reading frames (ORF) of the
indicated genes; (left panel) the probes against CYH2 were either
directed against the entire ORF or (right panel) exclusively against its
intron. (Asterisks) 39-Extended transcripts. 18S rRNA and U3
snoRNA were detected with end-labeled oligonucleotides. (C) High-
resolution Northern analysis of ACT1 and ASC1 39 ends. Total RNA
from a wild-type strain treated with cordycepin as described in A was
treated with RNase H in the presence of oligonucleotides comple-
mentary to the 39 end of the ORF of the (left panel) ACT1 or (right
panel) ASC1 genes, respectively. Below each gel a scheme indicates the
relative location of the oligonucleotide used to target RNAse H and
the distribution of observed 39 ends (I to V for ACT1; and I to IV for
ASC1).
Effects of cordycepin on RNA metabolism in yeast
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Moreover, the microarray data sug-
gested that cordycepin treatment of the
wild type resulted inmore transcripts that
were increased rather than decreased (Fig.
3C). This was surprising since we ob-
served a loss of cellular poly(A) associated
with cordycepin treatment (Fig. 2A).
These observations may indicate that
global levels of transcript bodies (which
were detected in the microarray) and of
poly(A) tails [which were detected in the
poly(A) analysis] were differentially af-
fected by the drug. Interestingly, RNAs
derived from dubious open reading
frames (dubious ORFs) were over-repre-
sented in the category of increased tran-
scripts (Fig. 3C, 44%). A Gene Ontology
(GO) analysis revealed, furthermore, that
cytoplasmic components were decreased
and unknown components were approx-
imately twofold increased under this con-
dition (Fig. 3D). Unknown components
are largely constituted by dubious ORFs
that also include cryptic unstable tran-
scripts (CUTs) (Wyers et al. 2005). CUTs
are rapidly degraded by the nuclear
exosome in a reaction that is strongly
stimulated by the noncanonical TRAMP
poly(A) polymerase complex (Wyers et al.
2005; Houseley et al. 2006). To test
whether cordycepin interfered with this
pathway, we probed by Northern blot for
the abundance of the well-characterized
CUT NEL025c in wild-type, exosome
(Drrp6), and TRAMP (Dtrf4) mutant
strains. The CUT was barely detectable
in wild type (Fig. 3E). In contrast,
NEL025c was stabilized in Drrp6 and
Dtrf4 strains, as expected, and cordycepin
enhanced this effect, resulting in a striking
accumulation of extended transcripts.
Taken together, these observations are
consistent with the idea that the increase
of transcript levels following cordycepin
treatment can partially be explained by
elevated levels of CUTs and extended
CUT containing RNAs.
Most interestingly, we observed a
highly significant up-regulation of ATP
synthesis pathways in pap1-1 strains
including, among others, mRNAs en-
coding proteins involved in nucleotide
precursor generation (P-value = 2.69
E-35), mitochondrial electron transport
(P-value = 3.17 E-25), and oxidative
FIGURE 3. The pap1-1 mutation neutralizes the effects of cordycepin. Gene expression
profiling was done with wild-type and pap1-1 strains following a shift for 1 h to medium
lacking or containing 20 mg/mL cordycepin, respectively. All experiments were performed in
triplicate. (A) Heat map of gene expression changes of cordycepin treated wild-type and
nontreated and treated pap1-1 mutant strains relative to the untreated wild-type control. Rows
represent genes, and columns represent average values obtained from three independent
measurements for the indicated condition; only those 3920 features were represented that gave
three values each for all three conditions. Clustering was done with Spearman Row correlation
(substance and row) using Acuity 4.0. The color code indicates the distribution of log2 ratios.
(B) Scatterplot of gene expression changes (log2 ratios). (Upper graph) Plots signals obtained
with the pap1-1 strain in the absence (y-axis) and the presence (x-axis) of cordycepin. (Lower
graph) Signals obtained with the pap1-1 strain in the absence of cordycepin (y-axis) are plotted
against signals obtained with cordycepin-treated wild-type (x-axis). (C) The table displays the
numbers of RNA transcripts that changed at least twofold (log2 value 61) relative to untreated
wild type in the respective conditions. The numbers of transcripts that were derived from
dubious open reading frames are indicated in percent in brackets. (D) Transcripts that were
increased under the indicated conditions were subjected to Gene Ontology analysis using the
SGD slim mapper (http://www.yeastgenome.org/). The number of genes in the individual
compartments is presented in percent of all analyzed genes. Also indicated is the background
distribution of all genes. (E) Northern blot analysis of total RNA obtained from wild-type and
mutant strains following growth in the absence and presence of 20 mg/mL cordycepin. The
CUT NEL025c was detected using a random primed labeled probe. (Asterisk) Indicates a
transcript that accumulates due to Pap1 dependent 39 end formation at a downstream gene
(Wyers et al. 2005).
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phosphorylation (P-value = 1.43 E-40). Moreover, mito-
chondrial components were strongly over-represented in
the GO term analysis (Fig. 3D). This may indicate that less
effective Pap1 stimulated the cell to increase ATP pro-
duction, suggesting that the pap1-1 mutant had an
increased ratio of ATP/CoTP in the presence of cordycepin.
Since this ratio may determine cordycepin toxicity (see
above), enhanced ATP synthesis may underlie the observed
cordycepin resistance of pap1 mutants. To further test this
idea, we supplemented cordycepin-containing medium
with adenine. Adenine was used instead of ATP because
yeast do not have an adenosine transporter (Maser et al.
1999). Figure 4A shows that excess adenine was sufficient to
suppress the growth-inhibitory effect of the drug on a wild-
type strain, whereas growth of pap1 mutant strains was not
noticeably affected.
Measurement of the cellular ATP content revealed
significantly increased levels in pap1-2 and pap1-5 strains
at 25°C compared to wild type (Fig. 4B). Following growth
at semipermissive temperature (33°C), all tested mutant
strains displayed markedly (two- to fourfold) increased
ATP levels compared to the wild-type control. These data
support the conclusion that ATP levels were elevated in
response to less active poly(A) polymerase in the tested
temperature-sensitive mutants.
Genome-wide identification of cordycepin targets
The yeast gene deletion collection (Winzeler et al. 1999) is a
valuable tool to explore the molecular targets of therapeutic
agents and xenobiotics (Hillenmeyer et al. 2008). To iden-
tify mutants that displayed cordycepin-dependent growth
phenotypes, we tested more than 4800 haploid deletion
strains by spotting them as single drops on synthetic
minimal plates lacking or containing 20 mg/mL cordycepin.
Candidate strains were identified by visual inspection and
re-examined in two consecutive rounds by dropping
10-fold serial dilutions on plates containing 40 and 20
mg/mL cordycepin, respectively. This identified 155 sensi-
tive strains and five strains that showed increased resistance
(see also Fig. 1C). The mutants were categorized as strong
(57), medium (56), and weak (47) indicating the severity of
the growth difference and the relative confidence in the
observed phenotype. Figure 5A shows growth phenotypes
of selected strains, a full list of identified mutants is
supplied in Supplemental Data S1. The distribution of
GO components revealed that cordycepin targets were
distributed without bias in the individual cellular compart-
ments. Significant functional categories included ATPases
(P-value = 0.001) and chromatin binding (P-value = 0.003).
Several subunits of the transcriptional coactivator SAGA
(Spt3, Spt7, Spt8, and Spt20), the SWR1 chromatin remod-
eling ATPase, and its substrate, the H2A variant Htz1, were
found to be cordycepin-responsive.
A limitation of evaluating drug-dependent growth by
drop-test is that weak differences are difficult to detect. We
decided therefore to employ a quantitative approach to
measure the relative fitness of mutant strains in the absence
and presence of the drug by chemical-genetic profiling (Ooi
et al. 2006). In these experiments, all mutants of the
deletion collection were competitively grown in a single
culture, and the relative abundance of individual strains
was measured after zero, 12, and 18 generations in medium
lacking or containing 20 mg/mL cordycepin. Considering
only signals of at least twofold or higher, we identified 205
cordycepin responsive mutants after 12 generations and
496 mutants after 18 generations (complete data sets are
available in Supplemental Data S2). However, due to severe
growth defects, this procedure will not resolve signals for
around 300 to 400 strains (Decourty et al. 2008). The
strong increase of identified strains from 12 to 18 gener-
ations suggested that even small growth differences could
be resolved with this approach. The scatterplot shown in
Figure 5B revealed a strong correlation of signals obtained
after 12 and 18 generations, demonstrating that the smaller
data set was almost completely included in the larger one
underscoring the significance of the obtained results.
We could identify several groups of genes that were
significantly enriched and that are highlighted in Figure 5B.
This included 15 PEX genes (P-value = 2.42 E-10),
which are required for the biogenesis and proliferation of
FIGURE 4. Increased ATP levels in pap1 mutants. (A) Tenfold serial
dilutions of wild-type and pap1 mutant strains were spotted on SD
medium containing 20 mg/mL cordycepin that was supplemented
with 20 mg/mL adenine as indicated. The yeast were grown for 3 d at
25°C and photographed. (B) Wild-type and pap1mutants strains were
grown at 25°C or shifted for 1 h to 33°C as indicated and assayed for
ATP content. Represented in the graph are average values for ATP
content obtained from three independent yeast cultures; the error bars
display standard error.
Effects of cordycepin on RNA metabolism in yeast
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peroxisomes (Kiel et al. 2006). Since cordycepin caused
reduced growth of pex mutants (Fig. 5C; data not shown),
we suggest a role for these organelles in suppressing toxicity
of the drug. Interestingly, the catabolism of purines was
associated with peroxisomes in mam-
mals (Wanders and Waterham 2006). If
this holds true also for yeast, cordycepin
levels may be increased in pex mutants
due to decreased nucleotide turn-over
providing a plausible explanation for
the increased sensitivity to the drug.
Most interestingly, chromatin remod-
eling complexes (P-value = 1.03 E-06)
and the SWR1 complex (P-value = 8.90
E-07) were significantly enriched in
these profiling experiments, and the
same GO terms were also identified
with the drop-test procedure. Similarly,
the cordycepin-sensitive growth of mu-
tants lacking SAGA components Spt3
and Spt8 was reproduced in both
approaches. We were surprised to iden-
tify in this screen strains lacking the
Pan2 and Pan3 proteins as cordycepin-
sensitive. Pan2/3 form the Pab1p-
dependent poly(A) nuclease that acts
in the shortening of mRNA poly(A)
tails (Boeck et al. 1996; Brown et al.
1996) and that may act in the message-
specific maturation of poly(A) length
(Brown and Sachs 1998). In contrast,
we found that the absence of Pop2,
which is associated with the major yeast
deadenylase Ccr4 (Daugeron et al. 2001;
Tucker et al. 2002), suppressed cordy-
cepin toxicity (Fig. 1C). Thus, these
cordycepin-dependent phenotypes may
reflect partially antagonistic effects of
Pan2/3 and Ccr4/Pop2 deadenylase com-
plexes, respectively, on gene expression
in yeast.
Finally, we compared the results
obtained with the drop-test and func-
tional profiling approaches, respectively.
Figure 5D shows that a mere 37 mu-
tant strains were identified with both
procedures. Since only four of those over-
lapping mutants corresponded to multi-
drug-resistance genes (Parsons et al.
2006), this group of mutants appeared
particularly responsive to cordycepin.
The limited overlap is mainly due to
fact that a large fraction of mutants
identified in the drop-test (85 of 107
strains) escaped the analysis by func-
tional profiling due to the slow growth phenotype. Inter-
estingly, we found that a published drop-test screen with
mycophenolic acid (Desmoucelles et al. 2002) also over-
lapped only little with results of a profiling experiment that
FIGURE 5. Identification of cordycepin-responsive haploid deletion mutants. (A) The growth
phenotypes of strains identified by drop-test screening were analyzed on medium containing
or lacking 40 mg/mL cordycepin as indicated. Strains were grown for 3 d at 30°C and
photographed. (B) Pools of all viable haploid deletion mutants from the systematic deletion
library were grown in complete liquid medium with or without 20 mg/mL cordycepin for 12 or
18 generations (Experiments 1 and 2, respectively) by serial dilutions. Cells were then collected,
the genomic DNA was extracted, and the barcode sequence tags associated with each gene
deletion were amplified by PCR and hybridized on barcode DNA arrays as described (Decourty
et al. 2008). The figure plots for each experiment (Experiment 1 on the x-axis and Experiment
2 on the y-axis) the log2 of the ratio for each deletion mutant of the barcode signal between the
cultures without and with cordycepin (computed as in Decourty et al. 2008). Negative log2
(ratios) indicate strains more sensitive to cordycepin than the average population of mutants.
Mutants in PEX genes, SWR1 complex genes, and SKI 2, 3, and 8 genes are color-coded as
indicated. Arrows and labels point to mutants with strong phenotypes. (C) Cordycepin-
sensitive growth phenotypes of pex mutants. The indicated strains were analyzed as described
in A. (D) Graph depicting the overlap of mutants identified in drop-test screening versus
functional profiling (after 12 generations). Also indicated are the numbers of multi-
drug-resistance genes that were identified with the individual procedures or which are shared,
respectively. In brackets the number of strains are indicated that are identified in the drop-test
screening that could not be analyzed by functional profiling due to slow growth of the mutants.
Holbein et al.
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we performed with the same drug
(S. Holbein, L. Decourty, A. Jacquier,
and B. Dichtl, unpubl.). These observa-
tions indicate that the outcomes of drug-
sensitivity screening of the yeast deletion
collection may be strongly dependent
on the employed approach.
Cordycepin-responsive strains are
connected to poly(A) metabolism
Since pre-mRNA 39 end formation is
targeted by cordycepin, drug mediated
growth phenotypes may indicate a func-
tional link to poly(A) metabolism. We
therefore tested whether cordycepin-
induced growth phenotypes can be
duplicated by combining selected muta-
tions with the temperature-sensitive
rna14-1 allele, which is defective in cleav-
age and polyadenylation of pre-mRNA
(Minvielle-Sebastia et al. 1994). Out of
24 double mutants tested, 11 were syn-
thetic lethal, 10 were synthetic sick, and
three did not exhibit a phenotype (Fig.
6A). These results suggested a functional
association of cordycepin-responsivemu-
tants and pre-mRNA processing.
To corroborate these findings, we
asked whether poly(A) metabolism was
affected in cordycepin-responsive strains
and analyzed the cellular poly(A) length
distribution of selected mutants. Figure
6B shows that wild-type strains ex-
hibited an even distribution of poly(A)
ranging from about 10 to 70 adenylate
residues (As). While the majority of
tested strains were similar to wild type,
some mutants showed marked accumu-
lation of short (up to 20 As), interme-
diate (up to 35 As), and long (up to 50
As) A-tracts. The maximum poly(A)
length of most strains was within the ex-
pected range ofz70 As. However, Dthp1
and Dsac3mutants (Gel I) showed some
hyperadenylation, a phenotype that was
previously associated with defective mRNA export (Hilleren
and Parker 2001). Somewhat curiously, Dpho85 and
Dpho80 RNAs did not give any poly(A) labeling (Gel II).
We recently showed that polyphosphate levels were ele-
vated in these mutants, resulting in the inhibition of the in
vitro labeling reaction and pointing to a possible role for
this metabolite in regulating poly(A) polymerase (Holbein
et al. 2008). Short poly(A) tails were stabilized, for example,
in the Dxrn1 strain, that lacks 59–39 exonuclease activity
required for cytoplasmic mRNA turn-over (Gel III). This is
consistent with reports showing that the absence of Xrn1
stabilized mRNAs, which were decapped and maintained
residual 10 to 15 As following deadenylation (Muhlrad
et al. 1994). Other mutants with short A-tracts included
Dsac3, Dyke2 (Gel I), Dvps33, Dies3 (Gel III), and Drad6,
Dada2, Drpl21a, Dswc1 (Gel IV). Intermediate poly(A)
tracts were observed in the Dvps34 mutant (Gel II). Vps34
is a phosphatidylinositol 3-kinase that forms a complex with
FIGURE 6. Cordycepin-responsive mutants are linked to poly(A) metabolism. (A) Mutations
causing cordycepin sensitivity genetically interact with rna14-1. The temperature-sensitive
rna14-1 strain, carrying a URA3-marked plasmid containing the wild-type RNA14 gene, was
used for disruption of genes causing cordycepin sensitivity. Double mutants were challenged
with 5-flouroorotic acid (5-FOA) to force loss of the URA3-marked plasmid exhibiting the
phenotype of the double mutation. Shown are serial dilutions of indicated single and double
mutant strains on synthetic (SD) medium lacking or containing 5-FOA. Growth phenotypes
were categorized as synthetic lethal (no growth), synthetic sick (reduced growth), or normal
(no phenotype) when compared to the rna14-1 mutant alone. (B) Cellular poly(A) length
distribution in cordycepin-responsive strains. Total RNA was obtained from indicated mutant
strains and analyzed as described in the legend of Figure 2A, except that poly(A) tails were
resolved on 10% sequencing gels.
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Vps15 (Stack et al. 1993); interestingly, the Dvps15 mutant
was also identified in our screening and also displayed
aberrant poly(A) length distribution (Gel III). These ob-
servations suggested a role for the Vps34–Vps15 complex
or the signaling molecule phosphatidylinositol 3-phos-
phate, respectively, in poly(A) metabolism. Other mutants
that had accumulated A-tracts of intermediate length
included Dpep5, Dthp1 (Gel I), Dbud32 (Gel III), and
Dyor331c (Gel IV). The Dreg1 strain accumulated long
poly(A) tails (Gel IV). Interestingly, Reg1 is a regulatory
subunit for the type-1 protein phosphatase Glc7p that is
involved in glucose repression (Tu and Carlson 1995). The
poly(A) phenotype observed here may reflect a previously
described role for Reg1 in controlling mRNA translation in
response to nutrient status (Ashe et al. 2000) and may point
to a requirement for Reg1-Glc7 in the maintenance of
poly(A) tail length homeostasis.
DISCUSSION
We present a comprehensive study of the effects of cordy-
cepin in the yeast S. cerevisiae that was initiated to increase
the understanding of the molecular modes of action of this
drug, on the one hand, and, on the other hand, to exploit
its properties for the identification of novel genes that are
functionally connected to poly(A) metabolism.
It is well established that cordycepin can terminate RNA
synthesis when incorporated by RNA polymerases and
poly(A) polymerase (Horowitz et al. 1976; Muller et al.
1977). While this conclusion is supported strongly by in
vitro experiments, the effects of the drug in vivo remained
less well characterized. Consistent with previous reports
(Lecoq et al. 2001; Naula et al. 2003), our analyses support
the idea that CoTP rather than cordycepin is mediating the
toxicity of the drug in yeast. Since CoTP is an analog of
ATP, this nucleotide may interfere with numerous cellular
processes that require ATP binding or hydrolysis. While
this remains a viable possibility, our analysis of suppressors
of cordycepin toxicity identified mutants in three major
activities: (1) nucleotide synthesis pathways that are in-
volved in the conversion of cordycepin to CoTP; (2) poly(A)
polymerase; and (3) cytoplasmic mRNA turn-over reactions.
The latter observation suggested that mRNA stabilization
suppressed toxicity, supporting the idea that it is, in-
deed, the inhibition of RNA synthesis that was limiting
cell growth. Consistently, we observed strongly reduced
steady-state mRNA levels following cordycepin treatment.
This reduction of mRNA levels may result from the
inhibition of transcript synthesis by RNA polymerase II,
the abortion of poly(A) addition by poly(A) polymerase, or
the inhibition of other reactions that are necessary for
stable mRNA accumulation.
Unexpectedly, we observed cordycepin mediated pheno-
types that cannot be explained by the RNA chain termina-
tion potential of the drug. Particularly striking were rapid
effects on the 39 ends of ACT1 and ASC1 mRNAs. For
ACT1, it was suggested that a cluster of alternative poly(A)
sites guides 39 end formation and that the efficiency of
poly(A) site recognition may determine the relative usage
of these sites (Mandart and Parker 1995). Consistent with
this idea, several mutants in 39 end factors interfered with
ACT1 39 ends (Mandart and Parker 1995; Dichtl et al.
2002b; Kyburz et al. 2003). The duplication of these
phenotypes by cordycepin in the wild type was unexpected
since the preferred usage of site I was shifted to the more
distal site V, resulting in longer transcripts (Fig. 2C). Since
shorter RNAs would be predicted to result from chain
termination, we conclude that the defect at ACT1 did not
result from cordycepin-induced termination of RNA poly-
merase II transcription. The accumulation of mRNAs with
more distal 39 ends also argued against chain termination
during poly(A) synthesis by Pap1. The latter conclusion
was furthermore underscored by the positive effect that
cordycepin had on growth of pap1 mutants (see below).
Indeed, it was maybe one of the most surprising results of
this study that the drug did not enhance the growth defect
of pap1 mutants. Since the ACT1 defect was observed only
minutes following exposure of the yeasts to the drug, and
since the phenotype was suppressed in Dado1 cells, it was
probably directly mediated by CoTP. We also observed
heterogeneous 39 ends for ASC1 mRNA, and also in this
case cordycepin treatment affected their relative abundance
in favor of the more distal 39 ends. Therefore, similar
mechanisms may mediate the effects of cordycepin on
39 end formation on ACT1 and ASC1.
Another unexpected observation was the appearance of
extended CYH2 mRNAs in the presence of cordycepin.
Transcripts with discrete length appeared within minutes of
drug addition and extended several kilobases beyond the
normal 39 end of the pre-mRNA, strongly suggesting that
RNA chain termination was not the major consequence
of cordycepin treatment. Instead, cordycepin apparently
interfered with efficient 39 end formation at the CYH2
poly(A) site as was observed with ACT1 and ASC1 mRNAs.
In contrast to the latter transcripts, which harbor clusters of
poly(A) sites in their 39 UTR, extended CYH2 RNAs may
result from 39 end formation at the next available poly(A)
sites, which lie far downstream from the regular site. How
cordycepin reduces 39 end formation efficiency remains
unclear, but involved pathways may include the coupling of
39 end formation to transcription (Lykke-Andersen and
Jensen 2007). Consistent with this idea, we found that
mutations in kinases and phosphatases that act on the CTD
are hypersensitive to cordycepin (Fig. 1A).
Furthermore, our gene expression profiling experiments
revealed that cordycepin treatment caused an increase of
transcripts that were derived from dubious ORFs. This
included the well-studied CUT NEL025c, which is degraded
by exosome and TRAMP mediated mechanisms (Wyers
et al. 2005; Houseley et al. 2006). A satisfying explanation for
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the observed effects on NEL025c could be that TRAMP
mediated polyadenylation was inhibited following cordyce-
pin incorporation causing less efficient turn-over of the
RNA. Alternatively, it seems possible that exosome-mediated
degradation was impaired when the substrate RNA lacked a
39 hydroxyl moiety. However, the major effect of cordycepin
on NEL025c expression was the appearance of extended
transcripts, which were likely to result from 39 end forma-
tion at sites downstream from the Nrd1-dependent termi-
nator that normally guides 39 end formation of this
transcript (Fig. 3E; Arigo et al. 2006; Thiebaut et al. 2006).
Downstream termination on this transcription unit has been
shown to include a Pap1 dependent site, providing another
possible explanation for the accumulation of these and other
RNAs in the presence of the drug. Since the Nrd1 complex is
targeted to transcription units by serine 5 phosphorylated
CTD (Gudipati et al. 2008; Vasiljeva et al. 2008), it is
tempting to speculate that cordycepin treatment reduced the
coupling of 39 end formation to transcription also at
NEL025c, as we suggested above for ACT1, ASC1, and
CYH2 mRNAs.
Overall, our data support the idea that the observed
biochemical effects of cordycepin occurred largely inde-
pendently from RNA chain termination. This unexpected
conclusion may indicate that the nuclear concentration of
CoTP that built up under the conditions employed here
was sufficiently high to reduce the efficiency of 39 end
formation, but too low to cause significant chain termina-
tion either during transcription or polyadenylation. It will
be interesting to test whether the same conclusion may
apply to other organisms, be it prokaryotes or metazoans.
However, our work implies that the impact of cordycepin
on RNA synthesis has to be interpreted with caution and
that it cannot generally be reduced to the chain termination
potential of the drug. While the target of cordycepin action
remains to be identified, the ameliorating effects of cordy-
cepin on growth of pap1 mutants (Fig. 1B) suggested an
epistatic relationship between polyadenylation and cordy-
cepin action. Such an epistatic effect is consistent with the
idea that mutation of poly(A) polymerase and the presence
of cordycepin interfere with the same pathway (Schuldiner
et al. 2005; Segre et al. 2005).
Moreover, our analyses revealed that inactivation of
poly(A) polymerase provoked higher cellular ATP levels
in temperature-sensitive mutant strains. Our data are also
consistent with the idea that the CoTP:ATP ratio is an
important determinant for cordycepin toxicity, providing a
plausible explanation of how poly(A) polymerase mutants
suppressed cordycepin toxicity. Interestingly, a recent re-
port revealed an ATP-sensing mechanism to connect RNA
abundance to respiration (Amiott and Jaehning 2006).
Our results suggest a reverse flow of information and raise
the interesting possibility that the ‘‘efficiency’’ of gene
expression (in this case, of polyadenylation) is somehow
sensed and functionally linked to the energy status of the
cell. However, further analyses are required to untangle
this intriguing interplay of ATP homeostasis and 39 end
formation.
One of our motivations to analyze the effects of
cordycepin was to establish a correlation of drug mediated
phenotypes and functional classes of genes. Direct analysis
of mutants involved in RNA synthesis and turn-over
pathways clearly established cordycepin-responsive pheno-
types. Our screening approaches using the deletion collec-
tion of non-essential genes identified genome-wide targets
for the drug, and only a rather limited number of those
genes is known to be involved in RNA synthesis and
processing. This may reflect that genes involved in those
processes often are essential for cell viability and were
therefore not represented in the mutant collection that we
screened. Nevertheless, we were able to link several func-
tional categories of mutants with high significance to
cordycepin action. This included chromatin associated
proteins like the SAGA and SWR1 complexes, but the
molecular reasons for cordycepin-responsive growth of the
respective mutants remain to be determined.
Our analyses demonstrated that cordycepin meditated
growth phenotypes can be useful indicators to identify
genes that are involved in poly(A) metabolism. Several
mutant strains were identified that showed aberrant
poly(A) length distribution profiles (Fig. 6B). While the
mechanistic relation of cordycepin-responsive growth and
poly(A) distribution remains unclear for certain mutants,
we can rationalize the situation in some cases. For example,
Dxrn1 strains stabilize decapped mRNAs that retain resid-
ual short poly(A) tails (Muhlrad et al. 1994). The apparent
accumulation of short poly(A) tracts can therefore reflect
defective mRNA turn-over, which we found to suppress the
toxic inhibition of RNA synthesis by cordycepin (Fig. 1C).
In addition to mRNA turn-over enzymes, translation ef-
ficiency is thought to affect mRNA stability (Meyer et al.
2004). In cordycepin-hypersensitive Dreg1 strains, the accu-
mulation of long poly(A) tracts may reflect a synergism
between deregulated translation (Ashe et al. 2000) and
reduced mRNA synthesis in the presence of cordycepin.
Other cordycepin phenotypes may have resulted from
enhancement of nuclear deficiencies that have an impact
on poly(A) metabolism. For example, Thp1 and Sac3 form
a nuclear-pore-associated complex that is required for
efficient mRNA export (Fischer et al. 2002). Nuclear
poly(A) accumulation may underlie the disturbed poly(A)
profiles observed here in Dthp1 and Dsac3 strains, and less
efficient gene expression in these strains likely synergized
with the toxic effects of cordycepin. Moreover, it seems
possible that loss of control of adenylation or deadenylation
activities may contribute to poly(A) tail phenotypes in
certain mutants. Non-essential components involved in
poly(A) metabolism may primarily be involved in fine-
tuning and regulatory aspects of gene expression. In this
respect, it will be interesting to test, for example, which role
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signal-transduction pathways and signaling molecules like
the Vps34/Vps15 and its product phosphatidylinositol
3-phosphate play in the control of global poly(A) levels
during growth and development or in response to changing
environmental conditions. It seems likely that these and
other cordycepin-responsive pathways identified in this
work may help to uncover novel regulatory layers of
poly(A) metabolism.
MATERIALS AND METHODS
Growth and construction of yeast strains
The S. cerevisiae strains used in this study are listed in Table 1.
Yeast were grown in rich YPD medium (2% glucose, 2% bacto-
tryptone, 1% yeast extract) or synthetic complete or synthetic
drop-out media (2% glucose, 0.67% yeast nitrogen base, 13
amino acids). Cordycepin (Sigma-Aldrich) was supplemented at a
concentration of 20 mg/mL unless stated otherwise. For synthetic
interaction analyses, kanMX4-marked alleles were amplified from
haploid mutant strains (Winzeler et al. 1999) and transferred into
the rna14-1 mutant background. Loss of URA3-marked plasmids
was forced on SD plates containing 1 mg/mL 5-FOA (Zymo
Research).
Drug sensitivity screening
For drop-test screening, all haploid mutants of the yeast gene
deletion collection (Euroscarf) (Winzeler et al. 1999) were grown
in 96-well microtiter plates and spotted on agar plates as single
drops. Growth was examined daily for a 5-d period by comparing
the drops on SD and SD cordycepin (20 mg/mL; Sigma-Aldrich)
medium. Candidate strains were re-examined in two consecutive
rounds by analyzing growth of 10-fold serial dilutions on SD
supplemented with 40 mg/mL and 20 mg/mL cordycepin, respec-
tively. The verified strains were then categorized as strong,
medium, and weakly responsive to cordycepin, reflecting the
relative confidence in the observed phenotype (Supplemental
Data S1).
Chemical-genetic profiling was done essentially as described
(Decourty et al. 2008). All haploid mutants of the yeast gene
deletion collection were pooled and cultured overnight in SD
medium at 30°C. At an OD600 of 1.0, the culture was diluted 20-
fold in SD medium lacking and containing 20 mg/mL cordycepin,
respectively, and the OD600 was monitored every hour. After zero,
12, and 18 generations, 10 mL of cell culture was harvested.
Genomic DNA extraction, labeling of the probes, hybridization to
arrays, and analysis of the data was done as described (Decourty
et al. 2008). Data are available in Supplemental Data S2.
RNA analyses
RNA extractions were done with a hot-phenol method as pre-
viously described (Holbein et al. 2008). Northern blot analysis was
done with RNAs resolved either on 1.2% denaturing formaldeyde/
agarose gels or with high-resolution 6% polyacrylamide/8.3 M
urea gels (Dichtl et al. 2002b). ASC1, ACT1, ADH1, PGK1, and
CYH2 mRNAs were detected with 32P random prime labeled PCR
products (primer sequences are available upon request) corre-
sponding to parts of the open reading frames. For CYH2, a PCR
product was also used that encompassed intronic sequences; the
CUT NEL025c was detected with a labeled PCR product amplified
with forward GATTAACAGTTAGATCCAG and reverse GGACTT
TCAGATCAGTCAGTG primers. 18S rRNA (ACGAAAAATCAA
ATAC), U3 snoRNA (AGGACATTTCTATAGGAATCG), and
tRNALEU3 (GAACTCTTGCATCTTACGATAGC) were detected
with 59 end labeled oligonucleotides. RNase H analyses (Dichtl
et al. 2002b) and poly(A) tail labeling (Holbein et al. 2008) were
done as previously described. Northern filters and dried gels were
exposed to BAS-MS imaging plates (Fuji) and developed on a
FLA-7000 PhosphorImager (Fuji).
ATP measurements
ATP quantification was done as described (Freimoser et al. 2006).
One OD600 equivalent of yeast cells was pelleted, the supernatant
was discarded, 50 mL of 1 M sulfuric acid were added, and the
suspension was neutralized with 50 mL of 2 M NaOH and 100 mL
of Tris-malate buffer (1 M, pH 7.5, 6% neutral red solution [0.1%
neutral red in 70% ethanol]). Cell debris was pelleted by
centrifugation, 20 mL of the supernatant was added to 80 mL of
Tris buffer (20 mM at pH 8, 2 mM EDTA), and 4 mL of
phosphoenol pyruvate were added (2.5 mM PEP at pH 8, 0.125
M MgSO4, 0.312 M K2SO4). Five microliters of this sample were
TABLE 1. Yeast strains used in this study
Strain Genotype Source/reference
kin28-ts3 Mat a; leu2; trp1; ura3; ade2; ade3; lys2; kin28-ts3 Valay et al. (1995)
pap1-1 Mat a; ade1/ade2; lys2; gal? ; Ura3-52; pap1-1 Patel and Butler (1992)
pap1-2 Mat a; pap1::LEU2; pA-pap1-2-TRP1; ura3-1; his3-11 Walter Kellera
pap1-5 Mat a; pap1::LEU2; pA-pap1-5-TRP1; ura3-1; his3-11 Walter Kellera
pap1-7 Mat a; pap1::LEU2; pA-pap1-7-TRP1; ura3-1; his3-11 Walter Kellera
rat1-1 Mat a; ura3-52; leu2D1; hisD200; rat1-1 Amberg et al. (1992)
rna14-1 Mat a; ura3-1; trp1-1; ade2-1; leu2-3; 112; his3-11; 15; rna14-1 Minvielle-Sebastia et al. (1994)
rna15-1 Mat a; ura3-1; trp1-1; ade2-1; leu2-3; 112; his3-11; 15; rna15-1 Minvielle-Sebastia et al. (1994)
rpb1-1 Mat a; ura3-52; rpb1-1 Nonet et al. (1987)
S288C MATa; SUC2; gal2; mal; mel; flo1; flo8-1; hap1; ho; bio1; bio6 Mortimer and Johnson (1986)
ssu72-2 Mat a; ura3-1; trp1-1; ade2-1; leu2-3; 112; his3-11; 15; ssu72-2 Dichtl et al. (2002a)
ysh1-3 Mat a; ura3-1; trp1-1; ade2-1; leu2-3; 112; his3-11; 15; TRP1::ysh1 [ysh1-3-HIS3-CEN] Garas et al. (2008)
aGift (Biozentrum, University of Basel).
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added to 45 mL of luciferase buffer (10 mM Tris-H2SO4 at pH 7.4,
3.5 mM MgSO4). Following addition of 50 mL of luciferase
solution (Roche ATP Bioluminescence Assay kit CLS II), relative
light units emitted were measured in a luminometer (Lumat LB
9507; Berthold Technologies).
Microarray analyses
Wild-type S228C and pap1-1 were grown in SD medium at 25°C
to OD600 0.3, and growth was continued for 1 h in the presence or
absence of 20 mg/mL cordycepin. All subsequent steps will be
described elsewhere (Halbeisen and Gerber 2009). Shortly, RNA
was extracted from cell pellets using a hot-phenol method and
further purification with the RNeasy Micro Kit (QIAGEN). Ten
micrograms of total RNA were used for reverse transcription
using superscript II (Invitrogen) with oligo(dT) and pdN9
primers and Ambion spike control. Following RNA hydrolysis
and neutralization, DNA was concentrated to 9 mL using the
Microcon-30 concentrator (Amicon). NHS-Cy3 and NHS-Cy5
dyes (Amersham) were coupled to the DNA and purified using
the Qia-quick PCR purification kit (QIAGEN). The Cy3- and
Cy5-labeled cDNA samples were mixed and concentrated in
Microcon-30 concentrators (Amicon) to a final volume of 10.5
mL, and labeling efficiency was measured by NanoDrop using the
microarray application.
The concentrated labeled DNA was mixed with MWG form-
amide buffer (Ocimun Biosolutions), and poly(A) RNA was
added to a final concentration of 0.5 mg/mL. The mix was in-
cubated for 10 min at 80°C, loaded on Nexterion slides (carrying
70-mer oligo probes for 10,944 features), and hybridized over-
night at 42°C. Following washes in 23 SSC, 0.2% SDS and 23
SSC, and 0.23 SSC, the arrays were immersed in 100% ethanol to
fix the cDNA, dried by centrifugation, and scanned with Axon
instruments scanner 4000. Scanning parameters were adjusted to
similar fluorescent intensities in both channels, and data were
collected with GENEPIX 3.0 (Axon Instruments). Spots with
abnormal morphology were identified by eye and excluded from
further analysis. Arrays were normalized by the Stanford Micro-
array Database (SMD) (Gollub et al. 2003). The calculated log2
ratios were imported into Acuity 4.0 (Axon Instruments) and
filtered for regression correlation of >0.5 (filters for large
variations in the ratios of pixels within each spot) and a signal-
to-noise ratio of >2.5 (signal over background). Average log2
ratios were calculated from the triple experiments for each gene
spot. RNAs were considered as increased when the log2 ratio was
>1 and decreased when log2 was <!1. Further analysis of the data
was carried out with the Saccharomyces Genome Database GO
term finder (http://www.yeastgenome.org/). Microarray data were
deposited at GEO (http://www.ncbi.nlm.nih.gov/geo; GEO acces-
sion: GSE14619), and processed data are also available as
Supplemental Data S3.
SUPPLEMENTAL MATERIAL
Supplemental material can be found at http://www.rnajournal.org.
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